Cost Effectiveness Analysis of Avonex and CinnoVex in Relapsing Remitting MS

Cost Effectiveness Analysis of Avonex and CinnoVex in Relapsing Remitting MS

INTRODUCTION Multiple sclerosis is a chronic and degenerative neurological disease characterized by loss of myelin sheath of some neurons in brain and spinal cord. It is associated with high economic burden due to premature deaths and high occurrence of disabilities. The aim of the current study was to determine cost effectiveness of two major products of interferon 1a in patients with relapsin...

Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients.

AIM Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This study aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-β formulations in MS patients. MATERIALS & METHODS In this study, blood samples were collected from 70 MS patients undergoin...

cytokine patterns after therapy with avonex®, rebif®, betaferon® and cinnovex® in relapsing–remitting multiple sclerosis in iranian patients

Cost-Effectiveness Analysis of Peginterferon Beta-1a In Italian Relapsing Remitting Multiple Sclerosis Management.

Milan, Italy Cost-Effectiveness Analysis of Peginterferon Beta-1a in Italian Relapsing-Remitting Multiple Sclerosis Management Iannazzo S,1 Santoni L,2 Saleri C,2 Puma E,2 Vestri G,2 Giuliani L,1 Canonico PL,3 Centonze D4 1SIHS Health Economics Consulting, Torino, Italy; 2Biogen Italia, Milan, Italy; 3Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy; 4Centre ...

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran

BACKGROUND Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-utility from the Iranian healthcare perspectives of 4DMDs relative to symptom management alone in p...